MacroGenics to Sell Margenza Cancer Drug for $40 Million

Dow Jones

Oct 22, 2024

By Colin Kellaher

MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera Therapeutics for an initial $40 million.

MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year.

The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates.

MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 22, 2024 07:53 ET (11:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2477338690"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477338690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477338690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477338690","market":"fut","top_or_hot":-1,"title":"MacroGenics to Sell Margenza Cancer Drug for $40 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for an initial $40 million. \n</p>\n<p>\n  MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year. \n</p>\n<p>\n  The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates. \n</p>\n<p>\n  MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2024 07:53 ET (11:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MacroGenics to Sell Margenza Cancer Drug for $40 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMacroGenics to Sell Margenza Cancer Drug for $40 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-22 19:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for an initial $40 million. \n</p>\n<p>\n  MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year. \n</p>\n<p>\n  The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates. \n</p>\n<p>\n  MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2024 07:53 ET (11:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2477338690","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477338690","pubTimestamp":1729597980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera Therapeutics for an initial $40 million.MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year.The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates.MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MGNX":"MacroGenics Inc."},"translate_title":"MacroGenics将以4000万美元出售Margenza抗癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGNX":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  MacroGenics has struck a deal to sell the rights to its Margenza breast-cancer drug to fellow biopharmaceutical company TerSera Therapeutics for an initial $40 million. \n\n\n  MacroGenics on Tuesday said it is eligible to receive up to $35 million in additional sales milestone payments as part of the deal, which is slated to close by the end of the year. \n\n\n  The Rockville, Md., company said the transaction will let it focus on advancing its pipeline of oncology product candidates. \n\n\n  MacroGenics launched Margenza, its first commercial product, in 2021. In its annual report for 2023, MacroGenics said Margenza hadn't generated enough revenue to be profitable, and the company warned that the drug may never achieve or sustain profitability. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2024 07:53 ET (11:53 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}